Australia"s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced positive three-month interim efficacy results from the first 20 patients enrolled in the Phase 2 heart failure trial of the proprietary allogeneic, or "off-the-shelf", adult stem cell product Revascor(TM).
This week Nursing Standard published some misleading and speculative information regarding the NMC"s registration fee. The story, titled "Registration fees could increase as regulator goes into black", also included factually inaccurate information about the NMC"s diversity data collection exercise which will soon be launched.